Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Regorafenib in Stage IV Colorectal Cancer (NED)
NCT05382741Phase 2Unknown
- Sponsor
- IRCCS Ospedale Policlinico San Martino
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, regorafenib in colorectal cancer (CRC), sponsored by IRCCS Ospedale Policlinico San Martino. Status: unknown.
02
Drugs
durvalumabregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05382741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382741.